Skip to content
Open access

Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 57 references
Medicine

TL;DR

Biparatopic targeting of CD38 using CD38-STARs represents a promising strategy for the treatment of MM, including the rare cases in which daratumumab fails to bind due to CD38 mutations.

Abstract

Rationale Antibody recruiters are an innovative class of immunotherapeutics, comprising a tumor-binding module and an antibody-binding module to redirect endogenous antibodies toward target cells. Recruited antibodies can then induce Fc-dependent effector functions to lyse tumor cells. The clinical success of CD38-directed monoclonal antibodies daratumumab and isatuximab has established CD38 as a validated target for the treatment of multiple myeloma (MM). Since daratumumab treatment can result in antigen loss or mutation of the binding site, novel immunotherapeutics should explore different binding mechanisms for maximum efficacy. Here, we report the generation of CD38-specific trimeric antibody recruiters (CD38-STARs) using nanobodies, single variable immunoglobulin domains isolated from camelid heavy-chain antibodies. Methods We genetically fused two different CD38-specific nanobodies against distinct CD38 epitopes to a human immunoglobulin κ light chain-specific nanobody to generate two CD38-STARs (E2-E3-STAR and E3-E2-STAR) with biparatopic antigen-binding modules. We analyzed their CD38 binding characteristics and the capacity for simultaneous engagement of CD38 and IgG, IgM, or IgA. We evaluated the induction of complement-dependent cytotoxicity (CDC) against various CD38-expressing tumor cell lines in vitro and against primary MM patient cells ex vivo, comparing the CD38-STARs with monoparatopic bispecific antibody recruiters (BARs). Results Both CD38-STARs engaged CD38 by simultaneously binding two epitopes that are distinct from the epitope bound by daratumumab, resulting in improved avidity compared to monoparatopic CD38-specific BARs. CD38-STARs demonstrated concurrent binding to CD38 and human IgG, IgM, or IgA. CD38-STARs induced higher CDC against various CD38-expressing tumor cell lines in vitro compared to monoparatopic BARs or daratumumab. Ex vivo, CD38-STARs mediated significant CDC induction against primary myeloma cells, whereas monoparatopic BARs failed to achieve significant killing. Conclusion Biparatopic targeting of CD38 using CD38-STARs represents a promising strategy for the treatment of MM, including the rare cases in which daratumumab fails to bind due to CD38 mutations.

Read PDF

Similar papers

Open access Oct 2026

Reviving low-affinity glycan-targeting CAR with combinatorial design.

CD19CAR T cells demonstrate remarkable therapeutic efficacy in the treatment of B cell malignancies. A global limitation of conventional CD19CAR therapy is its mono-specificity. Thus, defining complementary targets to CD19 is critical to avoid target-dependent limitations. Alternatives to protein antigens include secon...

C. Forcados, H. Köksal, Eveline Scherer et al. · 0 citations
Open access Sep 2026

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma

Melanoma remains a highly aggressive malignancy, and many patients fail to achieve durable benefit despite immune checkpoint inhibitor (ICI) therapy. ICIs improve outcomes but lack tumor specificity and do not directly recruit T-cells to tumor cells resulting in substantial side effects, highlighting the need for targe...

N. Prakash, Sebastian Hörner, I. Hagelstein et al. · 0 citations
Open access Sep 2026

Combination Of Bispecific Antibodies Enable Targeted TNFRSF Agonism and Effective Antitumor Activity.

4-1BB is an inducible costimulatory molecule that requires receptor clustering to boost anti-cancer immune response. However, the clinical development of monoclonal antibodies targeting 4-1BB has been constrained by toxicities driven by systemic activation. To address this, bispecific antibodies (bsAbs) have been devel...

Lucie Diby, P. Malinge, V. Moine et al. · 0 citations
Review Sep 2026

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy.

By connecting atomic-level receptor recognition to clinical outcome, this review provides a mechanistic foundation for the rational design of next-generation CTLA-4 therapeutics with improved efficacy and reduced immune-related toxicity.

Enat Mengistu Leta, S. Syed, Geleta Negasa Binegde et al. · 0 citations
Open access Oct 2026

53L10 T-cell engager tribody for immunotherapy of multiple solid tumors

Cancer immunotherapy with immune checkpoint inhibitors (ICIs), i.e., antibodies targeting inhibitory ICs, such as PD-1, PD-L1, and CTLA-4, have successfully revolutionized cancer treatment. One of the most promising cancer immunotherapies is based on bi-specific T-cell engagers that simultaneously bind with one arm to...

M. Passariello, M. Belardo, Toshikazu Inoue et al. · 0 citations
Review Open access Aug 2026

Bispecific antibodies: current advances and future perspectives.

Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action that are not achieved by conventional monoclonal antibodies, including cell-cell bridging, modulation of multiple signaling pathways, and recruitment of diver...

Toshiya Hino, Yusuke Ito, Yuki Kagoya · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.